What happened
When the FDA's Pharmacy Compounding Advisory Committee met on 23 and 24 July, it worked through seven peptides and we covered the result. Less noticed was the line about what comes next. The agency said the committee will meet again before the end of February 2027 to consider five more.
The five are cathelicidin (LL-37), GHK-Cu, dihexa acetate, Melanotan II, and pegylated mechano growth factor. No public comment docket has opened for that session yet.
Three of those five are compounds people reading this already buy. GHK-Cu is one of the most searched things on this site. Melanotan II has a following that has nothing to do with compounding pharmacies. And dihexa acetate is the one worth stopping on.
The dihexa problem, in one paragraph
In April 2025 the Journal of Pharmacology and Experimental Therapeutics retracted the 2012 and 2014 papers that established how dihexa was supposed to work, after a Washington State University investigation found figures had been falsified or fabricated. We wrote that up when we found it: the two papers that explained how dihexa works were retracted for fabricated data. Vendor listings still reproduce the claims from those papers today.
So a compound whose mechanism rests on retracted work is now scheduled for a hearing about whether pharmacists should be allowed to compound it. Those two facts are not in conflict, exactly. A nomination is not an endorsement, and the committee's job is to look at the evidence and decide. But it does mean the evidence they look at will need to account for a retraction that most of the internet has not registered.
What it changes for you today
Nothing, immediately, and it's worth being precise about why.
This committee advises on the 503A Bulks List, which governs what a compounding pharmacy may make for a patient with a prescription. It does not govern the research-use market, which is where most people reading this actually buy. A compound can be added to that list and the research-grade supply chain carries on unchanged, and a compound can be rejected and the same is true.
What a hearing does change is attention. The July meeting produced a wave of coverage in which BPC-157 was described as approved, cleared and legal, none of which happened. Expect the same in February, and expect vendor listings to start borrowing the language within days of it.
The thing nobody else is saying
We looked, and as far as we can tell no consumer peptide site has covered the February slate at all. The trade press reported it in a sentence and moved on, because for a regulatory audience it's a scheduling note.
For you it's something else. It's eighteen months of advance warning about which five compounds are going to get a burst of confusing headlines, and which one of them is going to be discussed on the basis of a literature with a hole in it. If you buy GHK-Cu or Melanotan II, that's worth knowing before the news cycle rather than during it.
What we'll watch
Three things. Whether a public comment docket opens, because that's the point at which anyone, including you, can put something on the record. Whether the FDA accepts or rejects the July recommendations, which will tell us how much the committee's vote is actually worth. And whether the dihexa retraction appears anywhere in the briefing materials when they're published.
We'll cover each here as it happens.
Related on PPL
Our write-up of the July vote is at an FDA panel just backed BPC-157 and KPV by one vote, and if the legal picture is what you're actually trying to work out, is it legal walks through it without the jargon.